383 related articles for article (PubMed ID: 18343280)
21. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells.
Ahn MY; Lee J; Na YJ; Choi WS; Lee BM; Kang KW; Kim HS
Chem Biol Interact; 2009 May; 179(2-3):169-77. PubMed ID: 19070610
[TBL] [Abstract][Full Text] [Related]
22. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
23. Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
Park H; Lee YJ; Kim TH; Lee J; Yoon S; Choi WS; Myung CS; Kim HS
Int J Mol Med; 2008 Nov; 22(5):605-11. PubMed ID: 18949380
[TBL] [Abstract][Full Text] [Related]
24. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
[TBL] [Abstract][Full Text] [Related]
25. Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells.
Uehara N; Yoshizawa K; Tsubura A
Oncol Rep; 2012 Jul; 28(1):105-10. PubMed ID: 22484732
[TBL] [Abstract][Full Text] [Related]
26. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Fantin VR; Loboda A; Paweletz CP; Hendrickson RC; Pierce JW; Roth JA; Li L; Gooden F; Korenchuk S; Hou XS; Harrington EA; Randolph S; Reilly JF; Ware CM; Kadin ME; Frankel SR; Richon VM
Cancer Res; 2008 May; 68(10):3785-94. PubMed ID: 18483262
[TBL] [Abstract][Full Text] [Related]
27. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
Law M; Forrester E; Chytil A; Corsino P; Green G; Davis B; Rowe T; Law B
Cancer Res; 2006 Jan; 66(2):1070-80. PubMed ID: 16424043
[TBL] [Abstract][Full Text] [Related]
28. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2.
Klier M; Anastasov N; Hermann A; Meindl T; Angermeier D; Raffeld M; Fend F; Quintanilla-Martinez L
Leukemia; 2008 Nov; 22(11):2097-105. PubMed ID: 18685613
[TBL] [Abstract][Full Text] [Related]
29. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
[TBL] [Abstract][Full Text] [Related]
30. Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression.
Ferri N; Granata A; Pirola C; Torti F; Pfister PJ; Dorent R; Corsini A
Mol Pharmacol; 2008 Jul; 74(1):144-53. PubMed ID: 18413661
[TBL] [Abstract][Full Text] [Related]
31. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
32. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
Haritunians T; Mori A; O'Kelly J; Luong QT; Giles FJ; Koeffler HP
Leukemia; 2007 Feb; 21(2):333-9. PubMed ID: 17136116
[TBL] [Abstract][Full Text] [Related]
33. Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression.
Gao QZ; Lu JJ; Liu ZD; Zhang H; Wang SM; Xu H
Asian J Androl; 2008 Jul; 10(4):635-41. PubMed ID: 18097517
[TBL] [Abstract][Full Text] [Related]
34. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
[TBL] [Abstract][Full Text] [Related]
35. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
[TBL] [Abstract][Full Text] [Related]
36. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
37. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line.
Mazzanti R; Platini F; Bottini C; Fantappiè O; Solazzo M; Tessitore L
Biochem Pharmacol; 2009 Jul; 78(1):21-32. PubMed ID: 19447220
[TBL] [Abstract][Full Text] [Related]
39. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.
Kawamata N; Chen J; Koeffler HP
Blood; 2007 Oct; 110(7):2667-73. PubMed ID: 17606765
[TBL] [Abstract][Full Text] [Related]
40. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1.
Petrella A; D'Acunto CW; Rodriquez M; Festa M; Tosco A; Bruno I; Terracciano S; Taddei M; Paloma LG; Parente L
Eur J Cancer; 2008 Mar; 44(5):740-9. PubMed ID: 18295477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
